Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012 Apr;56(4):2173-7
Date
02/01/2012Pubmed ID
22290982Pubmed Central ID
PMC3318320DOI
10.1128/AAC.05913-11Scopus ID
2-s2.0-84858627256 (requires institutional sign-in at Scopus site) 52 CitationsAbstract
Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
Author List
Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KSMESH terms used to index this publication - Major topics in bold
AgedAnti-Bacterial Agents
Cohort Studies
Cross Infection
Drug Resistance, Bacterial
Enterobacteriaceae
Enterobacteriaceae Infections
Escherichia coli Infections
Female
Humans
Klebsiella Infections
Klebsiella pneumoniae
Male
Microbial Sensitivity Tests
Middle Aged
Treatment Outcome
beta-Lactamases
beta-Lactams
